Literature DB >> 23159693

A systematic review of randomized trials assessing human papillomavirus testing in cervical cancer screening.

Insiyyah Y Patanwala1, Heidi M Bauer, Justin Miyamoto, Ina U Park, Megan J Huchko, Karen K Smith-McCune.   

Abstract

Our objective was to assess the sensitivity and specificity of human papillomavirus (HPV) testing for cervical cancer screening in randomized trials. We conducted a systematic literature search of the following databases: MEDLINE, CINAHL, EMBASE, and Cochrane. Eligible studies were randomized trials comparing HPV-based to cytology-based screening strategies, with disease status determined by colposcopy/biopsy for participants with positive results. Disease rates (cervical intraepithelial neoplasia [CIN]2 or greater and CIN3 or greater), sensitivity, and positive predictive value were abstracted or calculated from the articles. Six studies met inclusion criteria. Relative sensitivities for detecting CIN3 or greater of HPV testing-based strategies vs cytology ranged from 0.8 to 2.1. The main limitation of our study was that testing methodologies and screening/management protocols were highly variable across studies. Screening strategies in which a single initial HPV-positive test led to colposcopy were more sensitive than cytology but resulted in higher colposcopy rates. These results have implications for cotesting with HPV and cytology as recommended in the United States.
Copyright © 2013 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23159693      PMCID: PMC3686555          DOI: 10.1016/j.ajog.2012.11.013

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  18 in total

1.  Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women.

Authors:  Anna-Barbara Moscicki; Yifei Ma; Charles Wibbelsman; Teresa M Darragh; Adaleen Powers; Sepideh Farhat; Stephen Shiboski
Journal:  Obstet Gynecol       Date:  2010-12       Impact factor: 7.661

Review 2.  Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies.

Authors:  George Koliopoulos; Marc Arbyn; Pierre Martin-Hirsch; Maria Kyrgiou; Walter Prendiville; Evangelos Paraskevaidis
Journal:  Gynecol Oncol       Date:  2006-11-03       Impact factor: 5.482

3.  Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial.

Authors:  Dorien C Rijkaart; Johannes Berkhof; Lawrence Rozendaal; Folkert J van Kemenade; Nicole W J Bulkmans; Daniëlle A M Heideman; Gemma G Kenter; Jack Cuzick; Peter J F Snijders; Chris J L M Meijer
Journal:  Lancet Oncol       Date:  2011-12-14       Impact factor: 41.316

4.  Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.

Authors:  Maarit Leinonen; Pekka Nieminen; Laura Kotaniemi-Talonen; Nea Malila; Jussi Tarkkanen; Pekka Laurila; Ahti Anttila
Journal:  J Natl Cancer Inst       Date:  2009-11-09       Impact factor: 13.506

5.  Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial.

Authors:  Guglielmo Ronco; Paolo Giorgi-Rossi; Francesca Carozzi; Massimo Confortini; Paolo Dalla Palma; Annarosa Del Mistro; Bruno Ghiringhello; Salvatore Girlando; Anna Gillio-Tos; Laura De Marco; Carlo Naldoni; Paola Pierotti; Raffaella Rizzolo; Patrizia Schincaglia; Manuel Zorzi; Marco Zappa; Nereo Segnan; Jack Cuzick
Journal:  Lancet Oncol       Date:  2010-01-18       Impact factor: 41.316

6.  A randomized controlled trial of Human Papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary results (HPV FOCAL Trial).

Authors:  Gina S Ogilvie; Dirk J van Niekerk; Mel Krajden; Ruth E Martin; Thomas G Ehlen; Kathy Ceballos; Stuart J Peacock; Laurie W Smith; Lisa Kan; Darrel A Cook; Wendy Mei; Gavin C E Stuart; Eduardo L Franco; Andrew J Coldman
Journal:  BMC Cancer       Date:  2010-03-24       Impact factor: 4.430

7.  Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial.

Authors:  N W J Bulkmans; J Berkhof; L Rozendaal; F J van Kemenade; A J P Boeke; S Bulk; F J Voorhorst; R H M Verheijen; K van Groningen; M E Boon; W Ruitinga; M van Ballegooijen; P J F Snijders; C J L M Meijer
Journal:  Lancet       Date:  2007-10-04       Impact factor: 79.321

8.  Human papillomavirus and Papanicolaou tests to screen for cervical cancer.

Authors:  Pontus Naucler; Walter Ryd; Sven Törnberg; Anders Strand; Göran Wadell; Kristina Elfgren; Thomas Rådberg; Björn Strander; Bo Johansson; Ola Forslund; Bengt-Göran Hansson; Eva Rylander; Joakim Dillner
Journal:  N Engl J Med       Date:  2007-10-18       Impact factor: 91.245

9.  HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial.

Authors:  Henry C Kitchener; Maribel Almonte; Claire Thomson; Paula Wheeler; Alexandra Sargent; Boyka Stoykova; Clare Gilham; Helene Baysson; Christopher Roberts; Robin Dowie; Mina Desai; Jean Mather; Andrew Bailey; Andrew Turner; Sue Moss; Julian Peto
Journal:  Lancet Oncol       Date:  2009-06-17       Impact factor: 41.316

10.  HPV screening for cervical cancer in rural India.

Authors:  Rengaswamy Sankaranarayanan; Bhagwan M Nene; Surendra S Shastri; Kasturi Jayant; Richard Muwonge; Atul M Budukh; Sanjay Hingmire; Sylla G Malvi; Ranjit Thorat; Ashok Kothari; Roshan Chinoy; Rohini Kelkar; Shubhada Kane; Sangeetha Desai; Vijay R Keskar; Raghevendra Rajeshwarkar; Nandkumar Panse; Ketayun A Dinshaw
Journal:  N Engl J Med       Date:  2009-04-02       Impact factor: 91.245

View more
  10 in total

Review 1.  Cervical cancer stem cells.

Authors:  Tingting Yao; Rongbiao Lu; Yizhen Zhang; Ya Zhang; Chenyang Zhao; Rongchun Lin; Zhongqiu Lin
Journal:  Cell Prolif       Date:  2015-12       Impact factor: 6.831

2.  Systematic Comparison of Different Meta-analyses, Systematic Reviews and HTA Reports on Cervical Cancer Screening based on Cytology or HPV Test.

Authors:  M Jentschke; P Hillemanns
Journal:  Geburtshilfe Frauenheilkd       Date:  2016-10       Impact factor: 2.915

Review 3.  Cervical cancer screening: A never-ending developing program.

Authors:  Ciro Comparetto; Franco Borruto
Journal:  World J Clin Cases       Date:  2015-07-16       Impact factor: 1.337

4.  A portrait of single and multiple HPV type infections in Brazilian women of different age strata with squamous or glandular cervical lesions.

Authors:  Leandro Santos de Araújo Resende; Sílvia Helena Rabelo-Santos; Luís Otávio Sarian; Rosane Ribeiro Figueiredo Alves; Andréa Alves Ribeiro; Luiz Carlos Zeferino; Sophie Derchain
Journal:  BMC Infect Dis       Date:  2014-04-22       Impact factor: 3.090

5.  Knowledge and perception of human papilloma virus vaccine among the antenatal women in a Nigerian tertiary hospital.

Authors:  Teddy E Agida; Godwin O Akaba; Aliyu Y Isah; Bissalla Ekele
Journal:  Niger Med J       Date:  2015 Jan-Feb

6.  Prediction of posthepatectomy liver failure using transient elastography in patients with hepatitis B related hepatocellular carcinoma.

Authors:  Jie-Wen Lei; Xiao-Yu Ji; Jun-Feng Hong; Wan-Bin Li; Yan Chen; Yan Pan; Jia Guo
Journal:  BMC Gastroenterol       Date:  2017-12-29       Impact factor: 3.067

7.  Cost-effectiveness analysis of primary human papillomavirus testing in cervical cancer screening: Results from the HPV FOCAL Trial.

Authors:  Ian Cromwell; Laurie W Smith; Kim van der Hoek; Lindsay Hedden; Andrew J Coldman; Darrel Cook; Eduardo L Franco; Mel Krajden; Ruth Martin; Marette H Lee; Gavin Stuart; Dirk van Niekerk; Gina Ogilvie; Stuart Peacock
Journal:  Cancer Med       Date:  2021-04-02       Impact factor: 4.452

8.  Knowledge and Acceptability of Human Papillomavirus Vaccination among Women Attending the Gynaecological Outpatient Clinics of a University Teaching Hospital in Lagos, Nigeria.

Authors:  Kehinde S Okunade; Oyebola Sunmonu; Gbemisola E Osanyin; Ayodeji A Oluwole
Journal:  J Trop Med       Date:  2017-12-19

9.  Reducing incidence of cervical cancer: knowledge and attitudes of caregivers in Nigerian city to human papilloma virus vaccination.

Authors:  Adaobi I Bisi-Onyemaechi; Ugo N Chikani; Obinna Nduagubam
Journal:  Infect Agent Cancer       Date:  2018-08-17       Impact factor: 2.965

10.  Parents willingness to vaccinate their daughter against human papilloma virus and its associated factors in Bench-Sheko zone, southwest Ethiopia.

Authors:  Alemnew Destaw; Tewodros Yosef; Biruk Bogale
Journal:  Heliyon       Date:  2021-05-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.